ADMA Biologics Inc (ADMA)

Gross profit margin

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Gross profit (ttm)	US$ in thousands	187,306	152,300	111,537	88,942	72,033	57,037	48,116	35,265	24,599	15,327	6,556	1,172	-7,494	-9,458	-14,164	-19,071	-13,571	-12,686	-10,908	-10,156
Revenue (ttm)	US$ in thousands	382,809	330,245	283,177	258,216	234,293	208,108	181,890	154,079	130,481	110,072	93,998	80,944	68,517	58,112	48,069	42,220	40,301	37,248	36,021	29,350
Gross profit margin		48.93%	46.12%	39.39%	34.44%	30.74%	27.41%	26.45%	22.89%	18.85%	13.92%	6.97%	1.45%	-10.94%	-16.28%	-29.47%	-45.17%	-33.67%	-34.06%	-30.28%	-34.60%

September 30, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $187,306K ÷ $382,809K
= 48.93%

The gross profit margin of ADMA Biologics Inc has shown a positive trend over the past quarters, indicating an improvement in the company's ability to generate profit from its core operations. The margin has increased steadily from a negative percentage in Dec 2019 to a positive 48.93% in Sep 2024, which suggests that the company has been able to effectively manage its production costs and enhance the efficiency of its revenue-generating activities. This steady improvement in gross profit margin is a positive sign for the financial health and operational performance of ADMA Biologics Inc.